Karyopharm Therapeutics | KPTI - Current Liabilities


Karyopharm Therapeutics reported $87.16M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Abbott USD 16.5B 1.91B Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Karyopharm Therapeutics USD 87.16M 12.06M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Novartis USD 32B 286M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Takeda JPY 2.61T 470.53B Dec/2025
Tectonic Therapeutic USD 9.37M 1.99M Sep/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Xencor USD 95.91M 9.42M Dec/2025